4-(4-Cbz-哌嗪)苯硼酸频那醇酯 | 1150561-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(4-Cbz-哌嗪)苯硼酸频那醇酯
• 中文别名: 4-(4-Cbz-哌嗪基)苯基硼酸,频哪醇酯
• 英文名称: benzyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate
• 英文别名: benzyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate
• CAS: 1150561-68-4
• 化学式: C₂₄H₃₁BN₂O₄
• 分子量: 422.332
• InChiKey: ZOHXVPNICYVOFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.44
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (S)-2-(4-methoxyphenyl)-7-methoxy-8-(3-((S)-7-methoxy-2-(trifluoromethylsulphonyl)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yloxy)propyloxy)-10-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10H,11aH)-dione 、 4-(4-Cbz-哌嗪)苯硼酸频那醇酯 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 以52%的产率得到benzyl 4-(4-((S)-7-methoxy-8-(3-(((S)-7-methoxy-2-(4-methoxyphenyl)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  WO2013/53871

  摘要：

  公开号：

文献信息

• PYRROLOBENZODIAZEPINES
  申请人：SPIROGEN SÀRL

  公开号：US20140234346A1

  公开（公告）日：2014-08-21

  A compound with the formula I: wherein: R 2 is of formula II: where A is a C 5-7 aryl group, X is selected from the group comprising: NHNH 2 , CONHNH 2 , formula III, formula IV, and either: (i) Q 1 is a single bond, and Q 2 is selected from a single bond and —Z—(CH 2 ) n —, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) Q 1 is —CH═CH—, and Q 2 is a single bond; R 12 is a C 5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C 1-7 alkyl, C 3-7 heterocyclyl and bis-oxy-C 1-3 alkylene; R 6 and R 9 are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; where R and R′ are independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups; R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NHRR′, nitro, Me 3 Sn and halo; either: (a) R 10 is H, and R 11 is OH, OR A , where R A is C 1-4 alkyl; (b) R 10 and R 11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R 10 is H and R 11 is SO z M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R″ is a C 3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, and/or aromatic rings; Y and Y′ are selected from O, S, or NH; R 6′ , R 7′ , R 9′ are selected from the same groups as R 6 , R 7 and R 9 respectively and R 10′ and R 11′ are the same as R 10 and R 11 , wherein if R 11 and R 11′ are SO z M, M may represent a divalent pharmaceutically acceptable cation.

  化合物的化学式为I：其中：R2的化学式为II：其中A为C5-7芳基基团，X选自包括：NHNH2，CONHNH2，化学式III，化学式IV的组合物，以及：（i）Q1是单键，Q2选自单键和-Z-（CH2）n-，其中Z选自单键，O，S和NH，n为1至3；或（ii）Q1为—CH═CH—，Q2为单键；R12为C5-10芳基基团，可选地被一个或多个取代基所取代，所述取代基选自卤素，硝基，氰基，醚基，C1-7烷基，C3-7杂环基和双氧-C1-3烷基；R6和R9独立选自H，R，OH，OR，SH，SR，NH2，NHR，NRR'，硝基，Me3Sn和卤素；其中R和R'独立选择自可选取代的C1-12烷基，C3-20杂环基和C5-20芳基基团；R7选自H，R，OH，OR，SH，SR，NH2，NHR，NHRR'，硝基，Me3Sn和卤素；或者：（a）R10为H，R11为OH，ORA，其中RA为C1-4烷基；（b）R10和R11在它们结合的氮和碳原子之间形成一个氮-碳双键；或（c）R10为H，R11为SOzM，其中z为2或3，M为一价的药用可接受阳离子；R″为C3-12烷基链，该链可以被一个或多个杂原子和/或芳环所打断；Y和Y'选自O，S或NH；R6'，R7'，R9'选自与R6，R7和R9相同的基团，R10'和R11'与R10和R11相同，其中如果R11和R11'为SOzM，则M可能表示二价的药用可接受阳离子。
• Pyrrolobenzodiazepines
  申请人：MEDIMMUNE LIMITED

  公开号：US09388187B2

  公开（公告）日：2016-07-12

  A compound with the formula I: wherein: R2 is of formula II: where A is a C5-7 aryl group, X is selected from the group comprising: NHNH2, CONHNH2, formula III, formula IV, and either: (i) Q1 is a single bond, and Q2 is selected from a single bond and —Z—(CH2)n—, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) Q1 is —CH═CH—, and Q2 is a single bond; R12 is a C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, nitro, Me3Sn and halo; where R and R′ are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR′, nitro, Me3Sn and halo; either: (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R″ is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, and/or aromatic rings; Y and Y′ are selected from O, S, or NH; R6′, R7′, R9′ are selected from the same groups as R6, R7 and R9 respectively and R10′ and R11′ are the same as R10 and R11, wherein if R11 and R11′ are SOzM, M may represent a divalent pharmaceutically acceptable cation.

  化合物的化学式为I：其中：R2的化学式为II：其中A是C5-7芳基基团，X选择自包括：NHNH2，CONHNH2，化学式III，化学式IV的群组，并且是：（i）Q1是单键，Q2选择自单键和—Z—（CH2）n—，其中Z选择自单键，O，S和NH，n为1到3；或者（ii）Q1是—CH═CH—，Q2是单键；R12为C5-10芳基基团，可选地被一个或多个取代基所取代，所述取代基选择自卤素，硝基，氰基，醚，C1-7烷基，C3-7杂环基和双氧-C1-3烷基；R6和R9独立地选择自H，R，OH，OR，SH，SR，NH2，NHR，NRR'，硝基，Me3Sn和卤素；其中R和R'独立地选择自可选取代的C1-12烷基，C3-20杂环基和C5-20芳基基团；R7选择自H，R，OH，OR，SH，SR，NH2，NHR，NHRR'，硝基，Me3Sn和卤素；或者：（a）R10是H，R11是OH，ORA，其中RA是C1-4烷基；（b）R10和R11在它们所连接的氮和碳原子之间形成氮-碳双键；或者（c）R10是H，R11是SOzM，其中z为2或3，M是单价的药学上可接受的阳离子；R"是C3-12烷基链，该链可以被一个或多个杂原子和/或芳香环所打断；Y和Y'选择自O，S或NH；R6'，R7'，R9'选择自与R6，R7和R9相同的基团，R10'和R11'与R10和R11相同，其中如果R11和R11'是SOzM，则M可以表示为二价的药学上可接受的阳离子。
• WO2013/53871
  申请人：——

  公开号：——

  公开（公告）日：——